Rick Kiessig Email & Phone Number

I'm Director, CEO, and Chief Science Officer of Kimer Med, an award-winning biotech company, which is working to eradicate viral disease and provide protection against future pandemics, by developing and commercialising a family of broad-spectrum antiviral therapeutics. I've spent my career working with incredibly bright people to solve complex problems in fields ranging from computer operating systems to rocket science. I’ve had an interest in biochemistry and human health since studying science at university. Having twins who were very sick served to turn that interest into a passion. Bringing together my business expertise, ability to work in teams to solve complex problems, and my background in science and health, I am dedicating my life to helping the world rid itself of the sickness and suffering caused by viral disease. Find out more about Kimer Med’s success (https://kimermed.co.nz/)

Listed skills include Asp.Net Mvc, .Net, Sql Server, Software Design, and 46 others.

• 

  Director And Ceo

  Kimer Med Limited

  Aug 2020 - Present - Nelson, New Zealand

  Growing and managing a small pharma company, whose scientists are developing broad-spectrum antivirals, with planned applications in humans around the world. Using a proprietary process (the VTose® Antiviral Platform), R&D is undertaken in a fully equipped PC-2 (BSL-2) laboratory in Nelson, New Zealand, leveraging Nelson’s internationally-renowned scientific community and global networks.  Kimer Med’s Platform can:Rapidly design and test new antiviral candidates  Customise antivirals to target different types of virus  Reduce drug discovery time (traditionally very slow)  Optimise our antivirals for greater efficacy and safety  Support  both treatment (after infection), and short-term prevention (before infection).  There are around 220 viruses that cause death and disease in humans, but there are only approved antivirals for 11 of them. With no antiviral available for  Dengue, and annual Dengue cases numbering more than 400 million, Kimer Med’s initial development focus is on an antiviral for Dengue. This alone is a NZ$3.8 billion annual opportunity.